<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-160846</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016</dc:title>
<dc:description xml:lang="en">With the advent of new disease-modifying drugs, the treatment of multiple sclerosis is becoming increasingly complex. Using consensus statements is therefore advisable. The present consensus statement, which was drawn up by the Spanish Society of Neurology's study group for demyelinating diseases, updates previous consensus statements on the disease. The present study lists the medications currently approved for multiple sclerosis and their official indications, and analyses such treatment-related aspects as activity, early treatment, maintenance, follow-up, treatment failure, changes in medication, and special therapeutic situations. This consensus statement includes treatment recommendations for a wide range of demyelinating diseases, from isolated demyelinating syndromes to the different forms of multiple sclerosis, as well as recommendations for initial therapy and changes in drug medication, and additional comments on induction and combined therapy and practical aspects of the use of these drugs (AU)</dc:description>
<dc:creator>Rodríguez-Antigüedad Zarrantz, A</dc:creator>
<dc:creator>Ara Callizo, JR</dc:creator>
<dc:creator>Landete Pascual, L</dc:creator>
<dc:creator>Moral Torres, E</dc:creator>
<dc:creator>Fernández Fernández, O</dc:creator>
<dc:creator>García Merino, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La incorporación de nuevos medicamentos para modificar el curso de la esclerosis múltiple y la complejidad de su uso plantea la conveniencia de utilizar consensos terapéuticos. El consenso actual ha sido elaborado por el grupo de enfermedades desmielinizantes de la Sociedad Española de Neurología y actualiza consensos previamente publicados. Se enumeran los medicamentos aprobados para la esclerosis múltiple con sus indicaciones oficiales. Se analizan aspectos relacionados con el tratamiento, como la presencia de actividad, la precocidad, el mantenimiento terapéutico, el seguimiento, el fallo terapéutico, los cambios de medicación y el tratamiento en situaciones especiales. Se elaboran indicaciones de tratamiento desde el síndrome desmielinizante aislado a las distintas formas de esclerosis múltiple detallando recomendaciones de tratamiento inicial, cambios de medicación, con consideraciones sobre terapia combinada e inducción y aspectos prácticos del uso de medicamentos (AU)</dc:description>
<dc:source>Neurologia;32(2): 113-119, mar. 2017.</dc:source>
<dc:identifier>ibc-160846</dc:identifier>
<dc:title xml:lang="es">Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d9296^s22057</dc:subject>
<dc:subject>^d37619</dc:subject>
<dc:subject>^d8676^s22048</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29594^s22057</dc:subject>
<dc:subject>^d3162^s22045</dc:subject>
<dc:subject>^d9296^s22080</dc:subject>
<dc:subject>^d52955^s22049</dc:subject>
<dc:subject>^d13339^s22048</dc:subject>
<dc:subject>^d29594^s22080</dc:subject>
<dc:subject>^d52955^s22048</dc:subject>
<dc:subject>^d13339^s22049</dc:subject>
<dc:subject>^d53262</dc:subject>
<dc:subject>^d9296^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201703</dc:date>
</metadata>
</record>
</ibecs-document>
